Femara (Letrozole) Tablets: Uses, Dosage, Safety and Interactions

Femara is a prescription medicine containing letrozole, an aromatase inhibitor. It lowers estrogen production in postmenopausal women and is used in specific hormone receptor-positive breast-cancer settings. It is an oncology medicine that should be prescribed and monitored by a cancer specialist. Femara is not a general hormone treatment, a weight-loss medicine, or an appropriate self-treatment for breast symptoms.

Estrogen can stimulate the growth of some breast cancers. By inhibiting aromatase, letrozole reduces estrogen levels after menopause. Whether it is suitable depends on tumour characteristics, menopausal status, disease stage, previous treatment, bone health, cardiovascular risk, liver function, and the overall cancer plan. Do not stop or change Femara without consulting the oncology team.

Patients with a valid prescription may buy Femara through an appropriately regulated pharmacy. The Femara price may vary by quantity, manufacturer, pharmacy, insurance, and oncology-support arrangements. If cost threatens access, contact the cancer clinic or pharmacist; do not delay treatment or use an unverified source.

Indications

Femara is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer, extended adjuvant treatment after prior tamoxifen therapy, and first- or second-line treatment of hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer in postmenopausal women. The exact treatment setting and duration must be determined by the oncology team.

Femara is not appropriate during pregnancy. It is not generally used in premenopausal women unless a specialist has selected a defined ovarian-suppression strategy. It does not replace surgery, radiotherapy, systemic therapy, imaging, pathology review, or surveillance when those are indicated. New pain, a breast change, neurological symptoms, or worsening breathlessness should be reported rather than attributed automatically to treatment.

Dosage

Take Femara exactly as prescribed, generally once daily with or without food. The standard tablet strength is 2.5 mg. Take it at a consistent time, do not take extra tablets after a missed dose, and do not share tablets. If a dose is forgotten, take it when remembered unless it is close to the next dose; then skip it and return to the usual schedule. Contact the oncology team if repeated doses are missed or vomiting prevents dosing.

Patients with a valid prescription may buy Femara 2.5 mg when that exact oncology-directed strength is prescribed. Patients with a valid prescription may buy Femara 2.5 mg only in the amount and duration selected by the cancer specialist. The Femara price is not a reason to reduce frequency, extend a supply, or alter the treatment plan.

Treatment duration depends on the cancer setting, recurrence risk, prior endocrine therapy, response, and tolerance. Some patients receive therapy for years. Keep appointments for monitoring and keep tablets in the original container, protected from moisture and out of reach of children. Patients using Femara with a valid prescription should know how to contact the oncology team for refills and urgent advice.

Safety Information

Do not use Femara if you have had a serious allergic reaction to letrozole or a component of the product. It can cause fetal harm and should not be used during pregnancy; discuss effective contraception with the oncology team when relevant. Tell the clinician about osteoporosis, fractures, high cholesterol, heart disease, prior stroke or blood clot, liver disease, kidney impairment, and all medicines.

Because estrogen reduction can decrease bone mineral density, clinicians may evaluate baseline bone health and arrange periodic monitoring or bone-protective treatment. Femara can also raise cholesterol. Common effects include hot flashes, joint or muscle pain, stiffness, fatigue, weakness, headache, nausea, dizziness, swelling, and weight changes. Report persistent symptoms, falls, or reduced mobility.

Seek urgent care for chest pain, shortness of breath, sudden weakness or trouble speaking, severe headache, signs of a fracture, jaundice, severe rash, facial swelling, or breathing difficulty. Cost should never cause patients to omit bone-health monitoring, laboratory review, or oncology follow-up.

Interactions

Do not combine Femara with estrogen-containing products, including hormone replacement therapy or many combined hormonal contraceptives, because estrogen can counteract the intended effect. Tamoxifen can reduce letrozole concentrations, and concurrent treatment is generally avoided. Letrozole may also require consideration with medicines metabolized through CYP2A6 or CYP2C19.

Tell the oncology team and pharmacist about all prescription medicines, supplements, herbal products, and topical or vaginal hormone preparations. Patients should buy Femara only with a valid prescription and obtain an interaction review before beginning another treatment. The Femara price does not confirm authenticity, compatibility, or suitability.

Medical disclaimer: This content is informational and does not replace advice, diagnosis, or treatment from a licensed healthcare professional. Femara is a prescription medicine, and patients should follow their prescriber’s directions and seek professional advice for questions about their treatment.